Chimerix, Inc. (CMRX)

NASDAQ: CMRX · IEX Real-Time Price · USD
1.95
-0.26 (-11.76%)
At close: Dec 9, 2022 4:00 PM
1.99
+0.04 (2.05%)
After-hours: Dec 9, 2022 5:50 PM EST
-11.76%
Market Cap 194.58M
Revenue (ttm) 33.06M
Net Income (ttm) 153.63M
Shares Out 87.63M
EPS (ttm) 1.69
PE Ratio 1.15
Forward PE 1.21
Dividend n/a
Ex-Dividend Date n/a
Volume 1,800,788
Open 2.13
Previous Close 2.21
Day's Range 1.95 - 2.17
52-Week Range 1.27 - 7.42
Beta 1.14
Analysts Buy
Price Target 7.65 (+292.3%)
Earnings Date Nov 3, 2022

About CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic... [Read more]

Industry Biotechnology
IPO Date Apr 11, 2013
CEO Michael Sherman
Employees 87
Stock Exchange NASDAQ
Ticker Symbol CMRX
Full Company Profile

Financial Performance

In 2021, Chimerix's revenue was $1.98 million, a decrease of -63.16% compared to the previous year's $5.37 million. Losses were -$173.24 million, 298.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CMRX stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 292.31% from the latest price.

Price Target
$7.65
(292.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Prov...

– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis –

1 day ago - GlobeNewsWire

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 week ago - Zacks Investment Research

Chimerix Responds to Rubric Capital Management

Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans

4 weeks ago - GlobeNewsWire

Rubric Capital Management Sends Letter to Chimerix Board of Directors

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. (“Chi...

4 weeks ago - Business Wire

Buy 3 of the Best Stocks by Using Net Income Ratio

Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.

Other symbols: RCUSVIST
1 month ago - Zacks Investment Research

Chimerix (CMRX) Beats Q3 Earnings Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 30.95% and 84.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November –

1 month ago - GlobeNewsWire

Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing de...

1 month ago - GlobeNewsWire

Chimerix (CMRX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties -

2 months ago - GlobeNewsWire

Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients f...

3 months ago - GlobeNewsWire

Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA's Discretion Over 10 Years –

3 months ago - GlobeNewsWire

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer ...

Other symbols: APDNBVNRYGOVXSIGATNXP
3 months ago - InvestorPlace

Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update

– ONC201 Phase 3 ACTION Study Planned to Initiate This Year –

4 months ago - GlobeNewsWire

Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022

DURHAM, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing de...

4 months ago - GlobeNewsWire

Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency

Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Heal...

Other symbols: BVNRYEBSGOVXSIGA
4 months ago - InvestorPlace

Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile

Stocks related to the treatment of monkeypox are heating up today on news that the U.S. is building a vaccine stockpile and will offer vaccine appointments to individuals who are at risk of contracting ...

Other symbols: EBSSIGABVNRY
5 months ago - InvestorPlace

Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada

DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...

5 months ago - GlobeNewsWire

Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

DURHAM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...

5 months ago - GlobeNewsWire

7 Penny Stocks That Could Triple in 2022

Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks. The post 7 Penny Stocks That C...

Other symbols: ADNASMBBOXDBRDSNNSOLO
5 months ago - InvestorPlace

7 Monkeypox Stocks That May Take Off in Q2

SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared fi...

Other symbols: ABTBVNRYEBSINOSIGATNXP
6 months ago - InvestorPlace

Chimerix to Present at Jefferies Global Healthcare Conference

DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...

6 months ago - GlobeNewsWire

7 Monkeypox Stocks to Watch Right Now

Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.

6 months ago - InvestorPlace

Vaccine-maker shares soar on monkeypox outbreak

CNBC's Meg Tirrell joins 'Squawk Box' to break down the companies with vaccines against monkeypox as multiple countries respond to a growing number of cases.

Other symbols: BVNRYEBSSIGA
6 months ago - CNBC Television

Are These 4 Stocks Smart Buys With the Monkeypox Outbreak?

The monkeypox opportunity could already be baked into the prices of these stocks.

Other symbols: BVNRYEBSSIGA
6 months ago - The Motley Fool